<DOC>
	<DOCNO>NCT02582749</DOCNO>
	<brief_summary>Newly diagnose metastatic prostate cancer subject bone metastasis accrue stratified randomize 2-arm Phase II trial . Subjects randomize 1:2 ADT ADT Radium-223 dichloride respectively .</brief_summary>
	<brief_title>Androgen Deprivation Therapy +/- Radium-223 Dichloride Metastatic Prostate Cancer With Bone Metastases</brief_title>
	<detailed_description>OUTLINE : This multi-center , randomize trial . STRATIFICATION FACTORS : Subjects stratify base serum total alkaline phosphatase baseline extent disease ( describe ) . Randomization occur within stratification group . - Extent Disease : &lt; 6 skeletal metastasis visceral metastasis versus ≥6 skeletal metastasis visceral metastasis . - Serum total alkaline phosphatase baseline : normal v abnormal . Abnormal alkaline phosphatase define &gt; 130 IU/L . Early Induction Late Induction status stratification criterion . TREATMENT SCHEDULE : CONTROL ARM A All subject receive androgen deprivation therapy LHRH agonist ( LHRH agonist leuprolide acetate goserelin acetate acceptable ) LHRH antagonist ( degarelix ) bilateral orchiectomy , dosage determine treat physician . Route administration cycle day administer per package insert . Androgen deprivation therapy LHRH agonist LHRH antagonist give continuously . All subject receive bicalutamide , 50 mg Oral ( PO ) Daily TREATMENT SCHEDULE : EXPERIMENTAL ARM B All subject receive androgen deprivation therapy LHRH agonist ( LHRH agonist leuprolide acetate goserelin acetate acceptable ) LHRH antagonist ( degarelix ) bilateral orchiectomy , dosage determine treat physician . Route administration cycle day administer per package insert . Androgen deprivation therapy LHRH agonist LHRH antagonist give continuously . All subject receive bicalutamide , 50 mg oral ( PO ) daily All subject receive Radium-223 dichloride , 50 kBq ( 1.35 microcurie ) per kg body weight , intravenous ( IV bolus ) every 28 day 6 injection The following laboratory value must obtain within 28 day prior registration protocol therapy : Hematopoietic : - Hemoglobin ( Hgb ) ≥ 8.0 g/dL ( 80 g/L ) without pack RBC transfusion - Platelets ≥ 100 K/mm3 - Absolute neutrophil count ( ANC ) ≥ 1.5 K/mm3 Hepatic : - Total Bilirubin ≤ 2 x institutional upper limit normal ( ULN ) except subject Gilbert 's Syndrome , must total bilirubin less 3.0 mg/dL - Aspartate aminotransferase ( AST , SGOT ) ≤ 2.5 x institutional ULN ( ≤ 5 x institutional ULN presence liver metastasis ) . - Alanine aminotransferase ( ALT , SGPT ) ≤ 2.5 x institutional ULN ( ≤ 5 × institutional ULN presence liver metastasis ) . Renal : - Estimated Creatinine Clearance Cockcroft-Gault formula ≥ 30 mL/min</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>All subject legally authorize representative must inform investigational nature study provide write informed consent HIPAA authorization release personal health information performance study relate procedure part routine medical care . NOTE : HIPAA authorization may include informed consent obtain separately . Men ≥ 18 year age time informed consent . Histological cytological evidence prostate adenocarcinoma . All subject must radiologic pathologic evidence skeletal metastasis ≥ 2 skeletal lesion baseline bone scan axial image bone pain within 28 day prior initiation androgen deprivation therapy . All subject must also radiographic assessment ( chest abdominal/pelvic CT MRI ) within 28 day initiation androgen deprivation therapy need measurable disease . ECOG ( Eastern Cooperative Oncology Group ) Performance Status 02 within 28 day prior registration . ECOG Performance Status 3 allow judge treat investigator attributable exclusively bone pain . Subjects must fall one two population : EARLY INDUCTION GROUP : Subjects start androgen deprivation therapy ( luteinizing hormonereleasing hormone ( LHRH ) agonist antagonist therapy without antiandrogen agent ) maximum 28 day registration otherwise meet eligibility criterion . LATE INDUCTION GROUP : Subjects NOT start androgen deprivation therapy ( luteinizing hormonereleasing hormone ( LHRH ) agonist antagonist therapy without antiandrogen agent ) . Antiandrogen receptor antagonist therapy must bicalutamide . Subjects already start antiandrogens must willing switch bicalutamide . Any prior androgendeprivation therapy finasteride neoadjuvant adjuvant therapy biochemical recurrence must discontinue least 6 month prior registration . Prior surgical treatment prostate cancer allow must complete least 14 day prior registration toxicity therapy must recover ≤ grade 1 per CTCAE version 4 criterion time registration . All subject , include surgically sterilize , must willing use effective method contraception ( barrier method birth control abstinence ) time inform consent sign 6 month completion protocol therapy . Subjects must consent bank whole blood , serum , plasma future unspecified study . Prior cytotoxic chemotherapy metastatic prostate cancer . Prior cytotoxic chemotherapy curative intent neoadjuvant adjuvant setting allow must complete least 6 month prior registration . No cytotoxic chemotherapy allow protocol specify therapy . Prior concomitant therapy ketoconazole , aminoglutethimide abiraterone acetate enzalutamide ( MDV3100 ) intent treat . Concurrent megestrol hot flash allow . Prior ongoing bisphosphonate ( e.g , . zoledronic acid ) RANKL inhibitor ( e.g . denosumab ) use NOT allow except use solely osteoporosis strictly per guideline indication . Bisphosphonate RANKL inhibitor initiate indication protocol specify therapy without consent sponsorinvestigator study . Prior systemic radiotherapy strontium89 , samarium153 , rhenium186 rhenium188 . Diagnosis aplastic anemia , pure red cell aplasia , myelodysplasia bone marrow failure state . Any neuroendocrine differentiation include small cell carcinoma histology cytology . No prior malignancy except nonmelanomatous skin cancer nonmuscle invasive bladder cancer adequately treat Stage I II cancer ( adequacy discretion treat investigator ) subject currently complete remission , cancer subject diseasefree least 3 year . History active CNS metastasis ( brain , leptomeningeal cord compression ) . Brain imaging study require eligibility subject neurologic sign symptom suggestive brain metastasis . Subjects neurological symptom recommend undergo head CT scan ( without intravenous contrast ) brain MRI ( without intravenous contrast ) exclude brain metastasis . If brain imaging study perform , must negative CNS disease . Skull bone involvement without neurological impact prostate cancer allow . Treatment investigational agent within 28 day prior registration . Subjects must treat investigational agent protocol specify therapy . Prior hemibody external radiation . Any external radiation therapy must complete least 14 day prior registration . Any toxicity therapy must recover ≤ grade 1 per CTCAE version 4 criterion time registration . Clinically significant infection judge treat investigator . Subjects must diagnose human immunodeficiency virus ( HIV ) infection , active chronic hepatitis B C , lifethreatening illness unrelated cancer , serious medical psychiatric illness could , investigator 's opinion , potentially interfere participation study . Subjects test hepatitis B C HIV infection screen consider investigator high risk infection . Known hypersensitivity bicalutamide . Known gastrointestinal ( GI ) disease procedure could interfere GI absorption tolerance bicalutamide , include difficulty swallow oral medication . Grade III/IV cardiac disease define New York Heart Association Criteria ( i.e. , subject cardiac disease result marked limitation physical activity result inability carry physical activity without discomfort ) , symptomatic pulmonary embolism within 3 month , unstable angina pectoris , myocardial infarction within 6 month , serious uncontrolled cardiac arrhythmia determine treat physician .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Androgen Deprivation Therapy</keyword>
	<keyword>Androgen Receptor Antagonist</keyword>
	<keyword>Radium-223 Dichloride</keyword>
	<keyword>Placebo</keyword>
</DOC>